As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled ...

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

Moderna (MRNA) announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union, Norway and North ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...